Delegated Regulation (EU) No 877/2013 is amended as follows:
Article 1 is replaced by the following:
This Regulation lays down specifications concerning the content of the reports that Member States whose currency is the euro are required to submit pursuant to Article 10(3) of Regulation (EU) No 473/2013.’;
the following new Article 2a is inserted:
1.Where a Member State is subject to enhanced surveillance solely as a result of having drawn on the Pandemic Crisis Support of the European Stability Mechanism, the in-year reporting requirement pursuant to Article 10 of Regulation (EU) No 473/2013 shall pertain to the use of the Pandemic Crisis Support funds to cover direct and indirect healthcare, cure and prevention-related costs related to the COVID-19 pandemic.
2.The reports shall include the table indicated in Annex II.’;
the title of the Annex is replaced by the following:
‘ANNEX I’;
the following new Annex II is added:
Costs related to the COVID-19 pandemic
| a The last year of the availability period or of a possible disbursement of the Pandemic Crisis Support (whichever is earlier) is also the last year of the reporting, unless the Member State has not yet used all the funds drawn. | ||||||||
| b Items and sub-items, as necessary, accompanied with the relevant explanations to allow the Commission to perform a meaningful assessment. | ||||||||
| c This can include, inter alia, spending on hospitals; cure and rehabilitative care, ambulatory cure and rehabilitative care, diagnostics, pharmaceuticals, preventive care, health administrations, and health related long-term care.’ | ||||||||
| Year 2020 | Year 2021 a | |||||||
|---|---|---|---|---|---|---|---|---|
| In EUR million Time series of actual data ending at quarter of the respective report to be submitted | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |
| Healthcare, cure and prevention costs directly related to the COVID-19 pandemic | ||||||||
| [Item] | ||||||||
| [Further items as necessary]b | ||||||||
| Part of overall public healthcare spending estimated to be directly or indirectly attributed to addressing the impact of COVID-19 on the healthcare system c | ||||||||
| [Item] | ||||||||
| [Further items as necessary]b | ||||||||
| Other indirect costs related to healthcare, cure and prevention due to the COVID-19 crisis | ||||||||
| [Item] | ||||||||
| [Further items as necessary]b | ||||||||